Glycated Albumin Market

Market players and various research organisations are engaged in developing novel diagnostic tests using glycated albumin in order to meet increasing demand from end-use industries. For instance, in 2016, according to a study published in journal Nephrology Dialysis Transplantation reported that glycated albumin might provide a valuable alternative for predicting mortality in diabetic patients on hemodialysis.
Furthermore, leading players in the market are focused on new product launches and its approval from regulatory bodies in order to retain leading position in the market. For instance, in 2011, Diazyme Laboratories received the U.S. Food and Drug Administration (FDA) approval for enzymatic glycated serum protein (GSP, Glycated Albumin) Assay Kit. It is a two part liquid stable reagent, which can be used with various types of automated clinical chemistry analyzers for diabetes management and screening.
Moreover, in 2015, Asahi Kasei Pharma Corporation received CE Marking for Lucica Glycated Albumin-L, an in vitro diagnostic assay kit for glycated albumin (GA-L) in Europe, which in indicated for the quantitative measurement of glycated albumin in human serum on compatible clinical chemistry analyzers.

Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

Mr. Shinde
Prophecy Market Insights
Netaji Nagar,
Katepuram Chowk
New Sangvi,
Pune - 411027.

This release was published on openPR.